Astrazeneca (AZN) Revenue (QoQ) (2009 - 2026)
Astrazeneca (AZN) Revenue (QoQ) (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
1,183.33% |
| Dec 31, 2025 |
-45.45% |
| Sep 30, 2025 |
37.50% |
| Jun 30, 2025 |
-89.19% |
| Mar 31, 2025 |
-90.92% |
| Dec 31, 2024 |
1,281.36% |
| Sep 30, 2024 |
1,375.00% |
| Jun 30, 2024 |
-91.11% |
| Mar 31, 2024 |
-83.75% |
| Dec 31, 2023 |
185.57% |
| Sep 30, 2023 |
-49.74% |
| Jun 30, 2023 |
614.81% |
| Mar 31, 2023 |
-82.91% |
| Dec 31, 2022 |
-11.24% |
| Sep 30, 2022 |
5,833.33% |
| Jun 30, 2022 |
-98.84% |
| Mar 31, 2022 |
-49.71% |
| Dec 31, 2021 |
310.40% |
| Sep 30, 2021 |
-28.57% |
| Jun 30, 2021 |
177.78% |
